2025.1.31

2024年

◎ Comparison of Nonrelapse Mortality After Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide Versus Single Umbilical Cord Blood Transplantation in Hematologic Disease.

Harada K, Kanda J, Hirayama M, Wada F, Uchida N, Tanaka M, Nakamae H, Tokunaga M, Ishiwata K, Onizuka M, Hasegawa Y, Fukuda T, Eto T, Kurita N, Kawakita T, Jinguji A, Ishimaru F, Atsuta Y, Nakasone H.Transplant Cell Ther. 2024 Nov 26:S2666-6367(24)00782-6. doi: 10.1016/j.jtct.2024.11.011. Online ahead of print.PMID: 39603416 Free article.

◎ Female-to-male allogeneic transplantation affects outcomes differently according to the type of haplo-transplantation.

Tamaki M, Kawamura S, Takano K, Nakamae H, Doki N, Ohigashi H, Maruyama Y, Ota S, Hiramoto N, Eto T, Yoshihara S, Matsuoka KI, Masuko M, Onizuka M, Kanda Y, Fukuda T, Atsuta Y, Yanagisawa R, Yakushijin K, Nakasone H.Cytotherapy. 2025 Feb;27(2):213-221. doi: 10.1016/j.jcyt.2024.09.007. Epub 2024 Oct 5.PMID: 39453336

◎ Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia.

Moriguchi M, Nakamae H, Nishimoto M, Sugita J, Yanada M, Toubai T, Hasegawa Y, Hino M, Nishida T, Kurita N, Sawa M, Fukuda T, Jinguji A, Ota S, Matsuoka KI, Eto T, Hiramoto N, Ando T, Kawamura K, Kanda Y, Atsuta Y, Ohbiki M, Nakasone H, Konuma T.Br J Haematol. 2024 Dec;205(6):2376-2386. doi: 10.1111/bjh.19825. Epub 2024 Oct 22.PMID: 39439234

◎ Impact of donor type on the outcomes of acute graft versus host disease to systemic corticosteroid therapy.

Shimomura Y, Kitamura T, Sugita J, Terao T, Satake A, Hirakawa T, Uchida N, Shimabukuro M, Tanaka M, Eto T, Hiramoto N, Kataoka K, Nakamae H, Takase K, Kawakita T, Arai Y, Takeda W, Ishimaru F, Fukuda T, Atsuta Y, Nakasone H, Kanda J.Bone Marrow Transplant. 2024 Dec;59(12):1763-1772. doi: 10.1038/s41409-024-02424-x. Epub 2024 Sep 30.PMID: 39349961

◎ Cytotoxicity of bendamustine, alone and in combination with novel agents, toward adult T-cell leukemia cells.

Osada N, Kikuchi J, Okada Y, Matsuoka S, Morishita K, Nakasone H, Furukawa Y.PLoS One. 2024 Sep 30;19(9):e0309533. doi: 10.1371/journal.pone.0309533. eCollection 2024.PMID: 39348376 Free PMC article.

◎ Superiority of BM over PBSC for recipients with pre-transplant lung dysfunction in HLA-matched allogeneic HCT.

Kawamura S, Tamaki M, Konuma T, Onizuka M, Sakaida E, Hayashi H, Doki N, Nishida T, Sawa M, Ohigashi H, Fukuda T, Ishikawa J, Matsuoka KI, Kawakita T, Tanaka M, Ishimaru F, Ichinohe T, Atsuta Y, Kanda Y, Yakushijin K, Kanda J, Nakasone H.Cytotherapy. 2024 Nov;26(11):1353-1361. doi: 10.1016/j.jcyt.2024.06.006. Epub 2024 Jun 12.PMID: 38958628

◎ Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era.

Okada Y, Nakasone H, Kawamura S, Takano K, Yoshimura K, Tamaki M, Matsuoka A, Ishikawa T, Meno T, Nakamura Y, Kawamura M, Takeshita J, Yoshino N, Misaki Y, Kusuda M, Tanihara A, Kimura SI, Kako S, Kanda Y.Haematologica. 2024 Nov 1;109(11):3593-3601. doi: 10.3324/haematol.2024.285256.PMID: 38899343 Free PMC article.

Kikuchi J, Hori M, Osada N, Matsuoka S, Suzuki A, Kakugawa S, Yasui H, Harada T, Tenshin H, Abe M, Nakasone H, Furukawa Y.Haematologica. 2024 Oct 1;109(10):3414-3418. doi: 10.3324/haematol.2024.285368.PMID: 38867588 Free PMC article. No abstract available.

◎ Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era.

Terao T, Matsuoka KI, Fuji S, Kawamura S, Toya T, Doki N, Uchida N, Tanaka M, Fukuda T, Sawa M, Ishikawa J, Nishida T, Ohigashi H, Maruyama Y, Fujiwara SI, Kanda Y, Ota S, Ishimaru F, Atsuta Y, Kanda J, Ogata M, Yakushijin K, Nakasone H.Bone Marrow Transplant. 2024 Sep;59(9):1224-1231. doi: 10.1038/s41409-024-02313-3. Epub 2024 May 25.PMID: 38796633

◎ [Evidence of GVHD/GVL in allogeneic hematopoietic stem cell transplantation from sex-mismatched donors].

Nakasone H.Rinsho Ketsueki. 2024;65(4):265-271. doi: 10.11406/rinketsu.65.265.PMID: 38684437 Japanese.

◎ Comparative Analysis of Allogeneic Bone Marrow Transplantation Outcomes Between Japanese and Non-Japanese Populations.

Yanagisawa R, Shindo M, Shinohara A, Kuwatsuka Y, Nakase K, Kimura F, Shingai N, Nishida T, Fukuda T, Sakurai M, Kurokawa M, Koike T, Ota S, Takada S, Onizuka M, Uchida N, Tanaka M, Noguchi M, Maruyama Y, Hagihara M, Ichinohe T, Atsuta Y, Kanda J, Nakasone H, Toubai T.Transplant Proc. 2024 Mar;56(2):416-421. doi: 10.1016/j.transproceed.2024.01.049. Epub 2024 Feb 9.PMID: 38336483

◎ Association of individual comorbidities with outcomes in allogeneic hematopoietic cell transplantation from unrelated adult donors versus unrelated cord blood: A study on behalf of the Donor/Source and Transplant Complications Working Groups of the Japanese Society for Transplantation and Cellular Therapy.

Konuma T, Harada K, Shinohara A, Uchida N, Shingai N, Ito A, Ozawa Y, Tanaka M, Sawa M, Onizuka M, Katayama Y, Hiramoto N, Nakano N, Kimura T, Kanda Y, Fukuda T, Atsuta Y, Nakasone H, Kanda J.Am J Hematol. 2024 Feb;99(2):263-273. doi: 10.1002/ajh.27174. Epub 2024 Jan 2.PMID: 38164974

◎ Development of an umbilical cord blood transplantation-specific nonrelapse mortality risk assessment score.

Okada Y, Usui Y, Hayashi H, Nishikubo M, Toubai T, Uchida N, Tanaka M, Onizuka M, Takahashi S, Doki N, Uehara Y, Maruyama Y, Ishiwata K, Kawakita T, Sawa M, Eto T, Ishimaru F, Kato K, Fukuda T, Atsuta Y, Kanda J, Yakushijin K, Nakasone H.Blood Adv. 2024 Mar 26;8(6):1359-1368. doi: 10.1182/bloodadvances.2023011837.PMID: 38163321 Free PMC article.

◎ Outcomes in human T-cell leukemia virus type I carriers after hematopoietic stem cell transplantation for diseases other than adult T cell leukemia/lymphoma: a Japanese national survey.

Nakano N, Nakasone H, Fuji S, Shinohara A, Suzuki R, Utsunomiya A, Eto T, Morishima S, Ikegame K, Kakinoki Y, Matsuoka KI, Mori Y, Suehiro Y, Uchida N, Ito A, Doki N, Ozawa Y, Kanda J, Kanda Y, Fukuda T, Atsuta Y, Ogata M.Lancet Reg Health West Pac. 2023 Sep 25;40:100902. doi: 10.1016/j.lanwpc.2023.100902. eCollection 2023 Nov.PMID: 38106528 Free PMC article.

◎ Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation.

Yanagisawa R, Koyama H, Yakushijin K, Uchida N, Jinguji A, Takeda W, Nishida T, Tanaka M, Eto T, Ohigashi H, Ikegame K, Matsuoka KI, Katayama Y, Kanda Y, Sawa M, Kawakita T, Onizuka M, Fukuda T, Atsuta Y, Shinohara A, Nakasone H.Bone Marrow Transplant. 2024 Mar;59(3):325-333. doi: 10.1038/s41409-023-02172-4. Epub 2023 Dec 16.PMID: 38104219

◎ Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status.

Konuma T, Yamasaki S, Ishiyama K, Mizuno S, Hayashi H, Uchida N, Shimabukuro M, Tanaka M, Kuriyama T, Onizuka M, Ishiwata K, Sawa M, Tanaka T, Ohigashi H, Fujiwara SI, Matsuoka KI, Ota S, Nishida T, Kanda Y, Fukuda T, Atsuta Y, Nakasone H, Yanada M; Adult Acute Myeloid Leukemia and Donor/source Working Groups of the Japanese Society for Transplantation and Cellular Therapy.Transplant Cell Ther. 2024 Feb;30(2):215.e1-215.e18. doi: 10.1016/j.jtct.2023.12.002. Epub 2023 Dec 9.PMID: 38081415

一覧へ戻る